Search results
Results from the WOW.Com Content Network
October 17, 2000—Title IV, Section 402 of the Children's Health Act of 2000 (P.L. 106–310) entitled "Reducing the Burden of Diabetes Among Children and Youth" specified that the NIH conduct long-term epidemiology studies, support regional clinical research centers, and provide a national prevention effort relative to type 1 diabetes.
They are suggested in clinical practice guidelines released by various national and international diabetes organizations. [12] [13] The targets are: Hb A1c of less than 6% or 7.0% if they are achievable without significant hypoglycemia [14] [15] Preprandial (before eating) BG: 3.9 to 7.2 mmol/L (70 to 130 mg/dL) [14]
An electronic forum, NGC-L for exchanging information on clinical practice guidelines, their development, implementation and use; An Annotated Bibliography database where users can search for citations for publications and resources about guidelines, including guideline development and methodology, structure, evaluation, and implementation.
This guideline is intended to summarise the available literature, the advice provided by existing national guidelines and the information from current national practice on the choice of comparator, and to outline some of the challenges arising when establishing what the comparator for a specific assessment should be.
The group has developed a wide range of evidence-based guidelines to improve quality of care and collaborated with a number of other stakeholders. [2] Since its establishment it developed several evidence-based guidelines or wherever possible expert consensus to drive quality of inpatient diabetes care.
The notion of an Institute to determine the clinical effectiveness of interventions first emerged at the end of John Major's Conservative Government as moves elsewhere were being made to set professionally agreed standards for clinical care. In 1997, the UK National Screening Committee (NSC) had been established by Sir Kenneth Calman and Muir ...
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
The American Association of Clinical Endocrinologists (AACE), which provides clinical practice guidelines for management of diabetes, retains thiazolidinediones as recommended first, second, or third line agents for type 2 diabetes mellitus, as of their 2019 executive summary, over sulfonylureas and α-glucosidase inhibitors.